Uses EUHASS data to study turoctocog alfa pegol side effects

This study follows male participants with hemophilia A who are already taking Esperoct® as preventive (regular) treatment. It aims to learn how well this medicine works in real-world use and monitor safety over time.

This study looks at how people with hemophilia A do when they have surgery while using the medicine Altuvoct (efanesoctocog alfa). It helps doctors learn more about surgical practices for this condition.

This is a study that follows how people’s joints are doing after they start (or switch to) Esperoct, a preventive hemophilia medicine. It mainly collects real-world health information to understand joint outcomes over time.

This study is tracking how well Alhemo works in people with hemophilia A or B who have developed inhibitors (antibodies that block treatment). It is for patients of any age who have already started taking Alhemo as part of their regular care.

This study looks at safety information using existing patient registry records, not new treatment visits. It may help researchers better understand side effects of nonacog beta pegol by using real-world data.

This study checks how well efanesoctocog alfa (a preventive factor VIII treatment) protects your joints over time in people with hemophilia A. It involves regular checkups, joint assessments, and tracking of any bleeding episodes.